Epstein–Barr Virus

EBV (Epstein–Barr Virus) — oncology-focused definition

EBV is a double-stranded DNA herpesvirus (HHV-4) that establishes latent infection in B lymphocytes and is associated with the development of several malignancies, particularly in immunocompromised or chronically infected patients.

Oncology relevance (for pharmacists):

• Oncogenic role: EBV promotes malignant transformation through latent viral proteins (e.g., LMP1, EBNA) that activate cell proliferation and anti-apoptotic pathways.
• EBV-associated cancers include:
  • Burkitt lymphoma
  • Hodgkin lymphoma
  • Post-transplant lymphoproliferative disorder (PTLD)
  • Nasopharyngeal carcinoma
  • Some gastric carcinomas
• Strong association in HIV/AIDS, transplant recipients, and patients on chronic immunosuppression.

Clinical significance:

• Diagnostic marker: EBV detected via EBER in situ hybridization or plasma EBV DNA viral load.
• Prognostic and monitoring tool: Rising EBV DNA may indicate disease activity or relapse, especially in PTLD and NK/T-cell lymphomas.
• Therapeutic implications:
  • Antivirals are not effective against latent EBV.
  • Management may include reduction of immunosuppression, rituximab, chemotherapy, or cellular therapies depending on disease type.

Key takeaway for oncology pharmacists:

EBV is a viral oncogenic driver and disease biomarker, influencing diagnosis, monitoring, and treatment strategy, particularly in hematologic malignancies.